Lipella pharmaceuticals announces completion of site initiation visit for phase 2a trial of lp-310 in oral lichen planus

Clinical testing of lp-310 expected to commence in mid-2024    patient recruitment is underway for phase 2a multicenter, dose-ranging study pittsburgh, pa., may 31, 2024 — lipella pharmaceuticals inc.
LIPO Ratings Summary
LIPO Quant Ranking